ANI Pharmaceuticals (ANIP)
(Real Time Quote from BATS)
$61.84 USD
-0.35 (-0.56%)
Updated Jul 22, 2024 12:00 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANIP 61.84 -0.35(-0.56%)
Will ANIP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIP
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
Other News for ANIP
ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Buy Rating Affirmed: Strategic Acquisition Poised to Boost ANI Pharmaceuticals’ Revenue and Market Presence
ANI Pharmaceuticals price target raised by $7 at H.C. Wainwright, here's why